BANK VONTOBEL/CALL/ELI LILLY & CO/960/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 02:04:23 2024-05-14 pm EDT | ||
| 0.79 EUR | +6.76% |
|
| Current month | -39.69% | ||
| 1 month | -49.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-14 | 0.79 | +6.76% |
| 24-05-13 | 0.74 | -13.95% |
| 24-05-10 | 0.86 | -15.69% |
| 24-05-09 | 1.02 | -6.42% |
| 24-05-08 | 1.09 | +0.93% |
Delayed Quote Deutsche Boerse AG
Last update May 14, 2024 at 02:04 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0LST |
| ISIN | DE000VD0LST8 |
| Date issued | 2024-02-19 |
| Strike | 960 $ |
| Maturity | 2024-09-20 (129 Days) |
| Parity | 10 : 1 |
| Emission price | 2.65 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.91 € |
|---|---|
| Lowest since issue | 0.59 € |
| Spread | 0.02 € |
| Spread % | 2.35% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
757.7
USD
Average target price
850.4
USD
Spread / Average Target
+12.24%
- Stock Market
- Warrants
- Warrant
